All News

RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
RheumNow Podcast square

Associations in Rheumatology (10.3.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
KNee.calcinosis.inflammatin

COLCHICORT Trial

Jack Cush, MD

The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.

Read Article
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
RheumNow Podcast square

A New RA Approval (8.1.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Read Article
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow ( View Tweet)

Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2

Dr. John Cush RheumNow ( View Tweet)
Post hoc analysis of Gout (CARES) trial (rx w/ ULT) showed remission @ 1yr increased from 37% to 63% at yr 6. In 6 yrs, 59% achieved remission 1+ times. Remission was signif assoc w/ age, race, Hi Dz severity, comorbidities, and febuxostat treatment https://t.co/uTOkch8VW6 https://t.co/Ykc7JV6m7r

Links:

Dr. John Cush RheumNow ( View Tweet)
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9
Dr. John Cush RheumNow ( View Tweet)
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
Dr. John Cush RheumNow ( View Tweet)
COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout: Highlights from APLAR 2025 Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Binit Vaidya aptly poses this slide on the gout paradox: evidence-based T2T tx exist yet many still have uncontrolled dse. How can we close this gap? - address barriers to tx adherence - motivation - px education - multidisciplinary approach to px care @rheumnow #APLAR25 https://t.co/IEn9PMAxH5

Links:

sheila RHEUMarampa ( View Tweet)
Colchicine for #gout patients with CV risk: - since it has a purely anti-inflammatory effect, risk of acute CV events in pts w/ high CV risk is reduced. vs. NSAIDs/steroids, colchicine remains to be a safer option for gout prophylaxis @rheumnow #APLAR25 https://t.co/WgfTcIleMd

Links:

sheila RHEUMarampa ( View Tweet)
SGLT2 inhibitors exert their anti-inflammatory effects by inhibiting activation of the NLRP3 inflammasome. Secondary analyses of RCTs show that SGLT2is can reduce the risk of incident #gout @RheumNow #ACR25 https://t.co/IWgyDYEQoZ

Links:

sheila RHEUMarampa ( View Tweet)
Gout Education Card for Patients - Info & Rules #1 https://t.co/uppST8OBLZ https://t.co/3Ry3erNJCL

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Diagnosis & Management #2 https://t.co/uppST8OBLZ https://t.co/sLF5WPeuA5

Links:

Dr. John Cush RheumNow ( View Tweet)
RA & GOUT? S. Korean study of 34,356 new RA pts vs 103,068 controls. RA had 2.7 X higher risk of gout vs non-RA. Seropos & Seroneg equal incr risk (aHR 2.8 & 2.6), slightly higher in SPRA(aHR 1.07). RA on b/tsDMARDs had lower risk (aHR, 1.93) vs Untreated (aHR, 2.78). https://t.co/P0oqq5bVnq
Dr. John Cush RheumNow ( View Tweet)
NEJM images: 55-year-old man with metastatic squamous-cell lung cancer Hx& 6-wk Hx firm, painful swelling RToe1 & RDIP3 w/ ulceration. Xray showed lytic lesions due to acrometastases - rare bony metastases distal to elbow or knee, that may may mimic gout or osteomyelitis https://t.co/1Fh1Cp9dm9
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×